Clinical TrialJun 2, 2026, 07:01 AM
Picard Medical's Emperor TAH Study Shows Stable Circulatory Support
AI Summary
Picard Medical, Inc. announced the successful completion of an acute in vivo implant study series for its next-generation Emperor Total Artificial Heart (TAH) Platform. The study, conducted at the University of Arizona and Banner University Medical Center, demonstrated stable full circulatory support and physiologic autoregulatory behavior in a large animal model, with no device-related intraoperative failures. This milestone advances the development of a fully implantable artificial heart system, aiming to enhance patient mobility and quality of life by building on the SynCardia TAH's established architecture.
Key Highlights
- Successfully completed acute in vivo implant study for next-generation Emperor Total Artificial Heart (TAH) Platform.
- Emperor TAH demonstrated stable full circulatory support across all three acute implant procedures.
- No device-related intraoperative failures were observed during the study.
- The system incorporates an independent dual motor ventricular design for side-specific control of circulation.
- Studies conducted in collaboration with The University of Arizona and Banner University Medical Center Tucson.
- Emperor TAH is designed to build on SynCardia's decades of clinical experience.
- Initial preclinical data from first-generation Emperor TAH presented at ACC and ISHLT 2026 conferences.
Price Impact
More from PMI